Therefore, we tested if GPX4 inhibition with RSL3 could be effective as a first-line therapy (Fig. 3K–O) by treating two paired HR-NB PDX models derived from the same patient (Table S1): LU-NB PDX3 is a primary treatment-responsive model with an overall ADR phenotype, and LU-NB PDX3-R is a chemoresistant relapse model with a primarily MES phenotype12. This evidence concerns the gene GPX4 and neuroblastoma.